老熟女高潮喷了一地_亚洲综合无码AV一区二区_国产在线第一区二区三区_一区二区乱子伦在线播放_久久99精品久久久久麻豆_亚洲人成色4444在线观看_大陆少妇xxxx做受_国内精品久久久久影视_亚洲 欧洲 日韩 综合二区_老司机精品无码免费视频

    • <nobr id="rd5ku"><small id="rd5ku"></small></nobr>
    <dl id="rd5ku"></dl>
    細胞程序性死亡蛋白1配體1(PDL1)單克隆抗體
    Monoclonal Antibody to Programmed Cell Death Protein 1 Ligand 1 (PDL1)
    CD274; PDCD1LG1; B7-H; B7H1; PD-L1; PDCD1L1; PDCD1-LG1; Programed Death Ligand 1
    • 細胞程序性死亡蛋白1配體1(PDL1)單克隆抗體產(chǎn)品包裝(模擬)
    • 細胞程序性死亡蛋白1配體1(PDL1)單克隆抗體產(chǎn)品包裝(模擬)
    • 細胞程序性死亡蛋白1配體1(PDL1)單克隆抗體IHC圖
    • MAA788Hu22.jpgFigure. Western Blot; Sample: Recombinant PDCD1LG1, Human.
    • 細胞程序性死亡蛋白1配體1(PDL1)單克隆抗體Western Blot; Sample: Human Serum; 
      Primary Ab: 2μg/ml Mouse Anti-Human PDCD1LG1 Antibody
      Second Ab: 0.2μg/mL?HRP-Linked Caprine Anti-Mouse IgG Polyclonal Antibody
      (Catalog: SAA544Mu19)
    • Certificate通過ISO 9001、ISO 13485質(zhì)量體系認證
    特異性
    該抗體是針對PDL1的小鼠單克隆抗體。在免疫組織化學(xué)染色和免疫印跡實驗中能識別PDL1。
    用法
    Western blotting: 0.01-2μg/mL;
    Immunohistochemistry: 5-20μg/mL;
    Immunocytochemistry: 5-20μg/mL;
    Optimal working dilutions must be determined by end user.
    儲存
    
            經(jīng)常使用則4°C保存。-20°C保存不超過兩年。避免反復(fù)凍融。
        
    穩(wěn)定性
    
            熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗決定，具體方法如下：在37°C孵育48小時，沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi)，在適當(dāng)?shù)臈l件下存儲，損失率低于5%。
        
    贈品
    相關(guān)產(chǎn)品
    編號適用物種：Homo sapiens (Human，人)應(yīng)用(僅供研究使用，不用于臨床診斷！)
    RPA788Hu02細胞程序性死亡蛋白1配體1(PDL1)重組蛋白Positive Control; Immunogen; SDS-PAGE; WB.
    RPA788Hu01細胞程序性死亡蛋白1配體1(PDL1)重組蛋白Positive Control; Immunogen; SDS-PAGE; WB.
    APA788Hu61細胞程序性死亡蛋白1配體1(PDL1)活性蛋白Cell?culture;?Activity?Assays.
    EPA788Hu61細胞程序性死亡蛋白1配體1(PDL1)真核蛋白Positive Control; Immunogen; SDS-PAGE; WB.
    PAA788Hu01細胞程序性死亡蛋白1配體1(PDL1)多克隆抗體WB; ICC/IF
    FAA788Hu01抗細胞程序性死亡蛋白1配體1(PDL1)多克隆抗體Flow cytometry.
    FAA788Hu41抗細胞程序性死亡蛋白1配體1(PDL1)多克隆抗體(藻紅素標記)Flow cytometry.
    FAA788Hu51抗細胞程序性死亡蛋白1配體1(PDL1)多克隆抗體(別藻藍蛋白標記)Flow cytometry.
    FAA788Hu81抗細胞程序性死亡蛋白1配體1(PDL1)多克隆抗體(異硫氰酸熒光素標記)Flow cytometry.
    MAA788Hu28細胞程序性死亡蛋白1配體1(PDL1)單克隆抗體WB; IHC; ICC; IP.
    MAA788Hu22細胞程序性死亡蛋白1配體1(PDL1)單克隆抗體WB; IHC; ICC; IP.
    RAA788Hu22細胞程序性死亡蛋白1配體1(PDL1)重組抗體WB; IF; ICC; IHC; IP; FCM.
    MAA788Hu21細胞程序性死亡蛋白1配體1(PDL1)單克隆抗體WB; ICC/IF
    MAA788Hu23細胞程序性死亡蛋白1配體1(PDL1)單克隆抗體WB; ICC/IF
    MAA788Hu24細胞程序性死亡蛋白1配體1(PDL1)單克隆抗體WB; IHC; ICC; IP.
    MAA788Hu25細胞程序性死亡蛋白1配體1(PDL1)單克隆抗體WB; IHC; ICC; IP.
    MAA788Hu27細胞程序性死亡蛋白1配體1(PDL1)單克隆抗體WB; IHC; ICC; IP.
    MAA788Hu29細胞程序性死亡蛋白1配體1(PDL1)單克隆抗體WB; IHC; ICC; IP.
    MAA788Hu26細胞程序性死亡蛋白1配體1(PDL1)單克隆抗體WB
    RAA788Hu21細胞程序性死亡蛋白1配體1(PDL1)重組抗體WB; IF; ICC; IHC; IP; FCM.
    LAA788Hu72細胞程序性死亡蛋白1配體1(PDL1)單克隆抗體(生物素標記)WB
    FAA788Hu82抗細胞程序性死亡蛋白1配體1(PDL1)單克隆抗體(異硫氰酸熒光素標記)Flow cytometry.
    WEA788Hu細胞程序性死亡蛋白1配體1(PDL1)檢測試劑盒(酶聯(lián)免疫吸附試驗法,寬范圍)Enzyme-linked immunosorbent assay for Antigen Detection.
    SEA788Hu細胞程序性死亡蛋白1配體1(PDL1)檢測試劑盒(酶聯(lián)免疫吸附試驗法)Enzyme-linked immunosorbent assay for Antigen Detection.
    SCA788Hu細胞程序性死亡蛋白1配體1(PDL1)檢測試劑盒(化學(xué)發(fā)光免疫分析法)Chemiluminescent immunoassay for Antigen Detection.
    LMA788Hu細胞程序性死亡蛋白1配體1(PDL1)等多因子檢測試劑盒(流式熒光發(fā)光法)FLIA Kit for Antigen Detection.
    PSA788Hu01細胞程序性死亡蛋白1配體1(PDL1)抗體對ELISA; CLIA; ELISPOT; Luminex; Immunochromatography and other Immunoassays.
    KSA788Hu01細胞程序性死亡蛋白1配體1(PDL1)檢測試劑盒DIY材料(酶聯(lián)免疫吸附試驗法)Main materials for "Do It (ELISA Kit) Yourself".
    參考文獻
    雜志參考文獻
    Chinese Journal of CancerLevel of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications[NCBI: PMC3937742]
    Leukemia.?High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial.[Pubmed:24732592]
    Diabetes?Metab Res Rev.PD‐L1 gene polymorphisms and low serum level of PD‐L1 protein are associated to type 1 diabetes in Chile[Pubmed:24816853]
    Lancet HaematolRatios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study[PubMed: 26686046]
    Eur J Cancer.?High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis.[Pubmed:27039170]
    Journal of Cancer Research and Clinical OncologySerum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer[article:10.1007]
    Journal of Hematology & OncologyPD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma[pubmed:27737703]
    Lung Cancer. High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer.[pubmed:28212990]
    OncotargetSoluble?programmed?death-ligand?1?(sPDL1) and?neutrophil-to-lymphocyte?ratio?(NLR)?predictssurvival?in?advanced?biliary?tract?cancer?patients?treated?with palliative chemotherapy.[pubmed:27780932]
    OncotargetHigh?post-treatment?serum?levels?of?soluble?programmed?cell?death?ligand?1?predict?earlyrelapse?and?poor?prognosis?in?extranodal?NK/T?cell?lymphoma patients.[pubmed:27105512]
    Oncotarget.?Soluble PD-L1: A biomarker to predict progression of autologous transplantation in patients with multiple myeloma[pubmed:27566569]
    Cancer Immunol Immunother.Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy.[pubmed:28349165]
    LeukemiaSoluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: a replication study and combined analysis of 508 patients[leu2016385a]
    MedicinePlasma levels of soluble programmed death ligand-1 may be associated with overall survival in nonsmall cell lung cancer patients receiving thoracic radiotherapy.[pubmed:28207525]
    Allergology International?Inverse correlation of soluble programmed cell death-1 ligand-1 (sPD-L1) with eosinophil count and clinical severity in allergic rhinitis patients[pubmed:27617656]
    MedicinePlasma levels of soluble programmed death ligand-1 may be associated with overall survival in nonsmall cell lung cancer patients receiving thoracic radiotherapy[PMC5319514]
    American Journal of Respiratory and Critical Care MedicineSoluble Programed Death Receptor 1 Ligand (sPD-L1) in Pleural Fluid of Patients with Malignant Pleural Mesothelioma (MPM)[Pdf:10.1164]
    Clinical Lung CancerSoluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non–Small-cell Lung Cancer[Pubmed:29859759]
    Journal of RheumatologyIncreased levels of soluble programmed death ligand 1 associate with malignancy in patients with dermatomyositis[Pubmed:29419471]
    Translational?OncologyHigh Serum Level of Soluble Programmed Death Ligand 1 is Associated With a Poor Prognosis in Hodgkin Lymphoma[Pubmed:29698935]
    Immunology?LettersIncreased levels of soluble co-stimulatory molecule PD-L1 (B7-H1) in the plasma of viraemic HIV-1+ individuals[Pubmed: 30236481]
    Journal of?Cancer?Research?and?Clinical?OncologyPre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma[Pubmed: 30267213]
    Annals?of?Surgical?OncologySoluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between?…[Pubmed: 30565045]
    American Journal of Reproductive ImmunologyIdentification of programmed cell death 1 and its ligand in the testicular tissue of mice[Pubmed: 30578744]
    PLoS?OneClinical significance of soluble programmed cell death-1 and soluble programmed cell death-ligand 1 in patients with locally advanced rectal cancer treated?…[Pubmed: 30807610]
    Endocrine ConnectionsElevated levels of soluble PD-L1 are associated with reduced recurrence in papillary thyroid cancer[Pubmed: 31252406]
    Scientific ReportsPrognostic implications of soluble programmed death-ligand 1 and its dynamics during chemotherapy in unresectable pancreatic cancer[Pubmed: 31366979]
    Critical Reviews in Oncology / HematologyThe Clinical Significance of Soluble PD-1 and PD-L1 in Lung Cancer[Pubmed: 31675543]
    PLoS OneClinical implications of APOBEC3A and 3B expression in patients with breast cancer[Pubmed: 32176735]
    CancersPredictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study[Pubmed: 32085544]
    Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma[Pubmed: 32054467]
    LIVER INTERNATIONALThe prognostic role of soluble transforming growth factor‐β and its correlation with soluble programmed death‐ligand 1 in biliary tract cancer[Pubmed: 32780918]
    CANCER IMMUNOLOGY IMMUNOTHERAPYPrognostic impacts of tumoral expression and serum levels of PD-L1 and CTLA-4 in colorectal cancer patients[Pubmed: 32577816]
    Soluble PD-L1: a potential immune marker for HIV-1 infection and virological failure[Pubmed: 32443313]
    Cancer Immunol ImmunotherThe clinical implication of soluble PD-L1 (sPD-L1) in patients with breast cancer and its biological function in regulating the function of T lymphocyte[33688997]
    Acta Biochim Biophys SinPrognostic prospect of soluble programmed cell death ligand-1 (sPD-L1) in cancer management[34180502]
    EMBO JMicroglial PD‐1 stimulation by astrocytic PD‐L1 suppresses neuroinflammation and Alzheimer's disease pathology[34825707]
    Mol PharmA Novel Small Cyclic Peptide-Based 68Ga-Radiotracer for Positron Emission Tomography Imaging of PD-L1 Expression in Tumors[34910492]
    Mol Hum ReprodMacrophage Associated Immune Checkpoint CD47 Blocking Ameliorates Endometriosis[Pubmed:35404426]
    Journal of NanobiotechnologyMicrobial hydrogen “manufactory” for enhanced gas therapy and self-activated immunotherapy via reduced immune escape[Pubmed:35705974]
    MedicinaAssessment of the RANTES Level Correlation and Selected Inflammatory and Pro-Angiogenic Molecules Evaluation of Their Influence on CRC Clinical Features: A?…[Pubmed:35208526]